Minimum clinically important differences in acute pain: A patient-level re-analysis of randomized controlled analgesic trials submitted to the US Food and Drug Administration

The lack of established minimum clinically important differences in acute pain has made it challenging to interpret efficacy in analgesic trials. We performed a patient-level re-analysis of double-blind, placebo-controlled trials submitted to the US Food and Drug Administration to estimate minimum c